Drug Trial Radar · NCT07203391
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Feb 1, 2026
Primary completion
Dec 1, 2027
Study completion Dec 1, 2029
Sponsor
- Lead sponsor
- St Vincent's Hospital, SydneyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
Conditions
- Uveal Melanoma, Metastatic
Interventions
roginolisibDrug
Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- • To determine the safety and tolerability of roginolisib and tebentafusp in HLA-A*02:01 positive patients advanced uveal melanoma (UM).Time frame: Through study completion, estimated average of 1 year
- • To establish a maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination of roginolisib and tebentafusp in HLA-A*02:01 positive patients advanced uveal melanoma (UM).Time frame: Through study completion, estimated average of 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
St Vincents Hospital
Sydney, New South Wales, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.